MEDIATORS OF SKELETAL MUSCLE HYPERTROPHY IN HUMANS

这项研究的广泛的长期目标是更好地了解老年男性骨骼肌肥大的控制机制。 这与老年男性相关，因为肌肉减少症或与年龄相关的骨骼肌质量损失在该人群中非常普遍。 具体而言，我们将研究改变循环睾酮浓度，阻力训练，以及这两种干预措施的组合对骨骼肌肥大和骨骼肌肥大的腐败介质的影响：胰岛素样生长因子I mRNA，胰岛素样生长因子I蛋白和卫星细胞活化（骨骼肌MyoD和肌细胞生成素的浓度）。 我们将用醋酸甲地孕酮和睾酮给药改变睾酮浓度，并在以下实验设计中用阻力训练诱导骨骼肌肥大：1）非干预对照组; 2）醋酸甲地孕酮给药; 3）醋酸甲地孕酮给药+阻力训练; 4）醋酸甲地孕酮给药+每周100 mg庚酸睾酮; 5）甲地孕酮+抗阻训练+庚酸睾酮100 mg/周。

The broad long-term objective of the proposed research is to better understand mechanisms controlling skeletal muscle hypertrophy in elderly men. This is relevant to elderly men as sarcopenia or the age related loss of skeletal muscle mass is highly prevalent in this population. Specifically we will be examining the effects of altered circulating testosterone concentrations, resistance training, and the combination of these two interventions on skeletal muscle hypertrophy and putatative mediators of skeletal muscle hypertrophy: insulin like growth factor I mRNA, insulin like growth factor I protein, and satellite cell activation (skeletal muscle concentrations of MyoD and myogenin). We will alter testosterone concentrations with megestrol acetate and testosterone administration and will induce skeletal muscle hypertrophy with resistance training in the following experimental design: 1) A non-intervention control group; 2) megestrol acetate administration; 3) megestrol acetate administration + resistance training; 4) megestrol acetate administration + 100 mg of testosterone enanthate per week; 5) megestrol acetate administration + resistance training + 100 mg of testosterone enanthate per week.